Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Chief Executive Officer 57 24/06/2022
Director of Finance/CFO 55 31/08/2025
Chief Tech/Sci/R&D Officer - 28/09/2025
Director TitleAgeSince
Chairman 57 13/05/2026
Director/Board Member 68 01/02/2024
Director/Board Member 46 13/11/2023
Date Insider Type Main position Quantity % Market Cap.
06-01Fiscal year

Director

9,764 0.0496%
06-01Fiscal year

Director

8,856 0.0450%
06-01Fiscal year

Director

10,913 0.0554%
Change 5-day change 1-year change 3-year change Capi.($)
+71.43%+22.32% - - 2.37M
-0.06%+7.42%+47.74%+156.28% 1,025B
+2.08%+6.22%+52.51%+47.96% 559B
+1.27%+4.72%+19.25%+63.24% 394B
-2.08%+3.06%+21.96%+15.20% 324B
+0.28%+3.42%+50.76%+8.03% 295B
-1.19%+3.16%+26.55%+16.39% 286B
+0.89%+4.76%+21.33%+31.29% 270B
-0.92%-2.94%-48.15%-50.62% 186B
+0.21%+5.00%+18.86%+57.56% 187B
Average +7.28%+3.10%+23.42%+38.37% 391.8B
Weighted average by Cap. +0.29%+4.02%+32.86%+66.25%
Logo Mallinckrodt PLC
Mallinckrodt plc is a global specialty pharmaceutical company consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company operates through two segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Company's Specialty Brands segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, and gastrointestinal products. Its Specialty Generics segment includes specialty generic drugs and active pharmaceutical ingredients (APIs). Its product portfolio includes Acthar Gel, INOmax, StrataGraft, Terlivaz, and Amitiza.
Employees
2,687
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW